DRDebora Glenda Lima de La Roque

Debora Glenda Lima de La Roque

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Debora Glenda Lima de La Roque has a total of 80 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Oropouche virus in Brazil: Assessing the risks and challenges for transfusion medicine

    by Lucca Rocha Policastro, Debora Glenda Lima de La‐Roque, Rodrigo Tocantins Calado, Dimas Tadeu Covas, Luiz Carlos Alcantara, Marta Giovanetti, Simone Kashima


  • Open Access

    SARS-CoV-2 Lineage P.4 Detection in Southeast Brazil: A Retrospective Genomic and Clinical Overview

    by Mirele Daiana Poleti, Jéssika Cristina Chagas Lesbon, Elisângela Chicaroni de Mattos Oliveira, José Salvatore Leister Patané, Luan Gaspar Clemente, Vincent Louis Viala, Gabriela Ribeiro, Jéssica Fernanda Perissato Pinheiro, Marta Giovanetti, Luiz Carlos Junior Alcantara, et al.

    São Paulo state has been the epicenter of the Coronavirus Disease 2019 (COVID-19) in Brazil, ranking first by state with over six million reported cases. In February 2021, the P.4 lineage was reported in 21 cities across the state by public health authorities due to the L452R mutation. Here, by analyzing 17,304 genome sequences of SARS-CoV-2 sampled between February and August of 2021 in 476 distinct cities in São Paulo, we assess the transmission dynamics of the P.4 lineage and other SARS-CoV-2 variants that were, at the time of the study, co-circulating in the state. Additionally, clinical parameters from the city of Araras, São Paulo (N = 251) were considered to estimate the potential risk and mortality rate associated with the P.4 lineage since its higher prevalence was observed in that city. Our data suggest a low frequency (0.55%) of the P.4 lineage across the state, with the gamma variant being the dominant form in all regions (90%) at that time. Furthermore, no evidence of increased transmissibility and disease severity related to the P.4 lineage was observed. The displacement through the time of different lineages in São Paulo highlights how challenging genomic surveillance appears to track the emergence of new SARS-CoV-2 lineages, which could better guide the implementation of control measures.


  • Open Access

    Dynamics of SARS-CoV-2 Variants of Concern in Vaccination Model City in the State of Sao Paulo, Brazil

    by Svetoslav Nanev Slavov, Debora Glenda Lima de La-Roque, Pericles Natan Mendes da Costa, Evandra Strazza Rodrigues, Elaine Vieira Santos, Josiane Serrano Borges, Mariane Evaristo, Juliana de Matos Maçonetto, Adriana Aparecida Marques, Jonathan Milhomens, et al.

    From a country with one of the highest SARS-CoV-2 morbidity and mortality rates, Brazil has implemented one of the most successful vaccination programs. Brazil’s first model city vaccination program was performed by the CoronaVac vaccine (Sinovac Biotech) in the town of Serrana, São Paulo State. To evaluate the vaccination effect on the SARS-CoV-2 molecular dynamics and clinical outcomes, we performed SARS-CoV-2 molecular surveillance on 4375 complete genomes obtained between June 2020 and April 2022 in this location. This study included the period between the initial SARS-CoV-2 introduction and during the vaccination process. We observed that the SARS-CoV-2 substitution dynamics in Serrana followed the viral molecular epidemiology in Brazil, including the initial identification of the ancestral lineages (B.1.1.28 and B.1.1.33) and epidemic waves of variants of concern (VOC) including the Gamma, Delta, and, more recently, Omicron. Most probably, as a result of the immunization campaign, the mortality during the Gamma and Delta VOC was significantly reduced compared to the rest of Brazil, which was also related to lower morbidity. Our phylogenetic analysis revealed the evolutionary history of the SARS-CoV-2 in this location and showed that multiple introduction events have occurred over time. The evaluation of the COVID-19 clinical outcome revealed that most cases were mild (88.9%, 98.1%, 99.1% to Gamma, Delta, and Omicron, respectively) regardless of the infecting VOC. In conclusion, we observed that vaccination was responsible for reducing the death toll rate and related COVID-19 morbidity, especially during the gamma and Delta VOC; however, it does not prevent the rapid substitution rate and morbidity of the Omicron VOC.


  • Open Access

    Correction: Lesbon et al. Nucleocapsid (N) Gene Mutations of SARS-CoV-2 Can Affect Real-Time RT-PCR Diagnostic and Impact False-Negative Results. Viruses 2021, 13, 2474

    by Jéssika Cristina Chagas Lesbon, Mirele Daiana Poleti, Elisângela Chicaroni de Mattos Oliveira, José Salvatore Leister Patané, Luan Gaspar Clemente, Vincent Louis Viala, Gabriela Ribeiro, Marta Giovanetti, Luiz Carlos Junior de Alcantara, Olivia Teixeira, et al.

    The authors hereby request the inclusion of two authors (Olivia Teixeira and Maria Cristina Nonato) in the recently published article in Viruses entitled “Nucleocapsid (N) gene mutations of SARS-CoV-2 can affect real-time RT-PCR diagnostic and impact false-negative results”

  • Open Access

    Nucleocapsid (N) Gene Mutations of SARS-CoV-2 Can Affect Real-Time RT-PCR Diagnostic and Impact False-Negative Results

    by Jéssika Cristina Chagas Lesbon, Mirele Daiana Poleti, Elisângela Chicaroni de Mattos Oliveira, José Salvatore Leister Patané, Luan Gaspar Clemente, Vincent Louis Viala, Gabriela Ribeiro, Marta Giovanetti, Luiz Carlos Junior de Alcantara, Olivia Teixeira, et al.

    The current COVID-19 pandemic demands massive testing by Real-time RT-PCR (Reverse Transcription Polymerase Chain Reaction), which is considered the gold standard diagnostic test for the detection of the SARS-CoV-2 virus. However, the virus continues to evolve with mutations that lead to phenotypic alterations as higher transmissibility, pathogenicity or vaccine evasion. Another big issue are mutations in the annealing sites of primers and probes of RT-PCR diagnostic kits leading to false-negative results. Therefore, here we identify mutations in the N (Nucleocapsid) gene that affects the use of the GeneFinder COVID-19 Plus RealAmp Kit. We sequenced SARS-CoV-2 genomes from 17 positive samples with no N gene detection but with RDRP (RNA-dependent RNA polymerase) and E (Envelope) genes detection, and observed a set of three different mutations affecting the N detection: a deletion of 18 nucleotides (Del28877-28894), a substitution of GGG to AAC (28881-28883) and a frameshift mutation caused by deletion (Del28877-28878). The last one cause a deletion of six AAs (amino acids) located in the central intrinsic disorder region at protein level. We also found this mutation in 99 of the 14,346 sequenced samples by the Sao Paulo state Network for Pandemic Alert of Emerging SARS-CoV-2 variants, demonstrating the circulation of the mutation in Sao Paulo, Brazil. Continuous monitoring and characterization of mutations affecting the annealing sites of primers and probes by genomic surveillance programs are necessary to maintain the effectiveness of the diagnosis of COVID-19.


  • Open Access

    Pesquisa do vírus T-linfotrópico humano (HTLV) em amostras de secreção cérvico-vaginal de mulheres, em Belém, Pará, Brasil

    by Cássia Cristine Costa Pereira, Débora Glenda de Lima La-Roque, Rosilma dos Santos Albuquerque, Ingrid Christiane Silva, Louise de Souza Canto Covre, Akim Felipe Santos Nobre, Maria de Nazaré Lima dos Reis, Izabela Mendonça de Assis, Josiellem Damasceno de Souza, Suellen Souza de Moraes, et al.

    O Pará está entre os estados brasileiros com as mais elevadas taxas de prevalências da infecção pelo vírus T-linfotrópico humano (HTLV) nas populações onde este vírus já foi investigado. A infecção por HTLV geralmente apresenta prevalência mais elevada em mulheres com mais de 40 anos e com relacionamento estável. Além disso, as mulheres são mais susceptíveis à aquisição do vírus por via sexual do que os homens. Neste contexto, este estudo teve como objetivo detectar o genoma do provírus de HTLV em secreção cérvico-vaginal, com posterior confirmação em amostras de sangue, visando assim, propor uma nova metodologia de rastreamento desta infecção. Foram investigadas 400 mulheres de novembro de 2015 a dezembro de 2019, em Belém, Pará, Brasil. A coleta de secreção cérvico-vaginal se deu durante a realização do exame de Papanicolaou, e a de sangue periférico, durante contato posterior. O DNA das amostras foi extraído e realizada a análise molecular por Nested-PCR, seguida de digestão enzimática por Taq I, para pesquisa da infecção pelos tipos HTLV-1 e HTLV-2. Cinco (1,25%) das 400 mulheres tiveram resultado positivo para HTLV em secreção, sendo três para HTLV-1 e duas para HTLV-2. Por dificuldade de contato, só foi possível a confirmação da infecção no sangue em uma destas cinco mulheres. Nossos achados sugerem ser possível utilizar amostras de secreção cérvico-vaginal como mais uma forma de rastreamento da infecção por HTLV em mulheres.


  • Open Access

    Análise dos níveis de carga proviral em portadores de HTLV-1 com diferentes condições de comprometimento neurológico

    by Izabela Mendonça de Assis, Mariângela Moreno Domingues, Danilo de Souza Almeida, Louise de Souza Canto Covre, Debora Glenda Lima de La-Roque, Ingrid Christiane Silva, Akim Felipe Santos Nobre, Mariza da Silva Borges, Cássia Cristine Costa Pereira, Barbara Brasil Santana, et al.

    Objetivos: Analisar os níveis da carga proviral (CPV) em portadores de HTLV-1 com diferentes condições de comprometimento neurológico. Metodologia: Estudo transversal, realizado de março a outubro de 2017, com 43 pacientes com HTLV-1, divididos em três grupos por ordem decrescente de envolvimento neurológico, segundo proposta atualizada dos critérios de diagnóstico clínico para HAM/TSP: Definidos para HAM/TSP (Grupo 1, n=7); Prováveis/Possíveis para HAM/TSP (Grupo 2, n=9); Sem HAM/TSP (Grupo 3, n=27). O teste ANOVA (um critério) foi utilizado para verificar a diferença entre as médias de CPV dos grupos (p-valor≤0,05). Resultados: Os grupos apresentaram os seguintes valores médios de CPV: G1=9.00±11.18; G2=1.88±3.92; G3=2.81±4.03 cópias/106 PBMC. Na comparação intergrupo, da diferença entre as médias de CPV, foi observada diferença significativa entre os grupos 1 e 2 e entre os grupos 1 e 3 (p